Study analysis · European Heart Journal · 2024
This diabetes drug shrinks fat around your heart—without making you lose weight.
A common diabetes medicine reduced fat around the heart by 3.4 mL after 36 weeks, even though people didn’t lose weight.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study found that a medicine called empagliflozin made a type of fat around the heart shrink a little bit more than a dummy pill did. But it wasn't the main goal of the original study—it was just a side check. So we know it happened, but we can't say for sure it's because of the medicine or if it matters for how people feel.
What’s the bottom line?
A study tested if a common diabetes medicine called empagliflozin can reduce fat around the heart in people with heart failure and diabetes or prediabetes.
How strong is this study?
The study was done really well—it randomly gave people the real medicine or a fake one, and no one knew who got which, which helps avoid bias. But since it was a small group and only a side part of a bigger study, we can't be 100% sure the results apply to everyone with heart problems.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
85 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=105)+8.2/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 569 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. The study is a randomized controlled trial with double blinding and a control group, which allows for causal inference. However, it is a post-hoc substudy with a small sample size and limited generalizability, which may reduce the strength of causal claims.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding statements were disclosed in the provided text; study appears independently conducted.
Independent Analysis Safeguards
- Observers were blinded to subject identification, scan date, clinical data, and randomization arm
- Scans with major artefacts were not analysed
The study is a post-hoc substudy of the SUGAR-DM-HF trial, but no funding sources, author affiliations, or conflicts of interest are disclosed in the provided text. While the trial may have industry funding (empagliflozin is a commercial drug), this is not stated here, so no assumption can be made.
Key takeaways
- 01
After 36 weeks, people taking empagliflozin had 3.4 mL less fat around their heart than those on placebo.
- 02
This reduction was small but statistically significant, and it happened even though body weight didn't change much, suggesting the drug may directly affect heart fat.
Surprising findings
- Empagliflozin reduced heart fat by 3.4 mL without significant weight loss.SGLT2 inhibitors are known for promoting weight loss, so it was unexpected that heart fat decreased independently—suggesting a direct effect on pericardial fat metabolism.
Practical takeaways
Patients with heart failure and diabetes/prediabetes may benefit from empagliflozin not just for blood sugar, but potentially for reducing harmful heart fat.
This was a posthoc substudy of a larger trial—methodology details like patient selection and imaging protocols were not fully reported.
low confidenceWhy this study matters
Fat Around the Heart Drops—Without Weight Loss
Empagliflozin reduced epicardial adipose tissue (EAT) volume by 3.4 mL compared to placebo after 36 weeks, independent of changes in BMI. This suggests the drug may directly affect heart fat, not just overall body fat.
Most people assume fat loss around organs requires weight loss—but here, a drug reduced heart fat without changing body weight, hinting at a targeted biological effect.
Heart Fat Is a Measurable Target
EAT volume was measured precisely using cardiovascular magnetic resonance (CMR) imaging, a high-resolution technique. The study found a statistically significant reduction (p=0.045) with a 95% CI of -6.7 to -0.1 mL.
For the first time, a drug’s effect on heart fat was quantified with advanced imaging—turning a theoretical link into a measurable outcome.
Effect Is Consistent Regardless of Starting Fat Level
The reduction in EAT volume from empagliflozin was not influenced by how much fat patients had at the start—whether they had high or low baseline EAT, the drug worked similarly.
This means the drug could help a broad group of patients, not just those with extreme fat buildup—making it potentially more widely applicable.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
A study tested if a common diabetes medicine called empagliflozin can reduce fat around the heart in people with heart failure and diabetes or prediabetes.
Research results
After 36 weeks, people taking empagliflozin had 3.4 mL less fat around their heart than those on placebo.
What this means - more context
This reduction was small but statistically significant, and it happened even though body weight didn't change much, suggesting the drug may directly affect heart fat.
This study investigates whether empagliflozin reduces epicardial adipose tissue (EAT) volume in patients with heart failure with reduced ejection fraction and type 2 diabetes or prediabetes.
In a posthoc substudy of a randomized trial, empagliflozin significantly reduced EAT volume by 3.4 mL compared to placebo after 36 weeks, independent of BMI changes, as measured by cardiovascular magnetic resonance.
Methods Used
Multicentre, randomised, double-blind, placebo-controlled trial; patients assigned 1:1 to empagliflozin 10 mg daily or placebo; EAT volume measured by cardiovascular magnetic resonance cine imaging at baseline and week 36; observers blinded to group assignment.
Main Finding
Empagliflozin reduced EAT volume by 3.4 mL (95% CI -6.7 to -0.1; p=0.045) compared to placebo at 36 weeks.
Confidence Level
Limited - based on abstract only, full methodology not available
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Posthoc substudy of a larger trial - not pre-specified as primary outcome
- •Sample size and power not fully reported in abstract
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
Empagliflozin reduced heart fat by 3.4 mL without significant weight loss.
SGLT2 inhibitors are known for promoting weight loss, so it was unexpected that heart fat decreased independently—suggesting a direct effect on pericardial fat metabolism.
Practical Takeaways
Patients with heart failure and diabetes/prediabetes may benefit from empagliflozin not just for blood sugar, but potentially for reducing harmful heart fat.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 569 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
Moderate probability
on the GRADE evidence scale
This study found that a medicine called empagliflozin made a type of fat around the heart shrink a little bit more than a dummy pill did. But it wasn't the main goal of the original study—it was just a side check. So we know it happened, but we can't say for sure it's because of the medicine or if it matters for how people feel.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Randomized controlled trial design
- Double-blinded
- Placebo-controlled
Weaknesses
- Post-hoc substudy, not pre-specified
- Full methodology not available - based on abstract only
- Small sample size
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
A study tested if a common diabetes medicine called empagliflozin can reduce fat around the heart in people with heart failure and diabetes or prediabetes.
Research results
After 36 weeks, people taking empagliflozin had 3.4 mL less fat around their heart than those on placebo.
What this means - more context
This reduction was small but statistically significant, and it happened even though body weight didn't change much, suggesting the drug may directly affect heart fat.
This study investigates whether empagliflozin reduces epicardial adipose tissue (EAT) volume in patients with heart failure with reduced ejection fraction and type 2 diabetes or prediabetes.
In a posthoc substudy of a randomized trial, empagliflozin significantly reduced EAT volume by 3.4 mL compared to placebo after 36 weeks, independent of BMI changes, as measured by cardiovascular magnetic resonance.
Methods Used
Multicentre, randomised, double-blind, placebo-controlled trial; patients assigned 1:1 to empagliflozin 10 mg daily or placebo; EAT volume measured by cardiovascular magnetic resonance cine imaging at baseline and week 36; observers blinded to group assignment.
Main Finding
Empagliflozin reduced EAT volume by 3.4 mL (95% CI -6.7 to -0.1; p=0.045) compared to placebo at 36 weeks.
Confidence Level
Limited - based on abstract only, full methodology not available
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Posthoc substudy of a larger trial - not pre-specified as primary outcome
- •Sample size and power not fully reported in abstract
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
Empagliflozin reduced heart fat by 3.4 mL without significant weight loss.
SGLT2 inhibitors are known for promoting weight loss, so it was unexpected that heart fat decreased independently—suggesting a direct effect on pericardial fat metabolism.
Practical Takeaways
Patients with heart failure and diabetes/prediabetes may benefit from empagliflozin not just for blood sugar, but potentially for reducing harmful heart fat.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 569 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
Moderate probability
on the GRADE evidence scale
This study found that a medicine called empagliflozin made a type of fat around the heart shrink a little bit more than a dummy pill did. But it wasn't the main goal of the original study—it was just a side check. So we know it happened, but we can't say for sure it's because of the medicine or if it matters for how people feel.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Randomized controlled trial design
- Double-blinded
- Placebo-controlled
Weaknesses
- Post-hoc substudy, not pre-specified
- Full methodology not available - based on abstract only
- Small sample size
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study was done really well—it randomly gave people the real medicine or a fake one, and no one knew who got which, which helps avoid bias. But since it was a small group and only a side part of a bigger study, we can't be 100% sure the results apply to everyone with heart problems.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
85 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=105)+8.2/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 569 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. The study is a randomized controlled trial with double blinding and a control group, which allows for causal inference. However, it is a post-hoc substudy with a small sample size and limited generalizability, which may reduce the strength of causal claims.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding statements were disclosed in the provided text; study appears independently conducted.
Independent Analysis Safeguards
- Observers were blinded to subject identification, scan date, clinical data, and randomization arm
- Scans with major artefacts were not analysed
The study is a post-hoc substudy of the SUGAR-DM-HF trial, but no funding sources, author affiliations, or conflicts of interest are disclosed in the provided text. While the trial may have industry funding (empagliflozin is a commercial drug), this is not stated here, so no assumption can be made.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Dr Brad Stanfield cite this study, drawing 1 claim from it.
- Very strong evidence
Randomized or controlled trials support this claim, alongside consistent supporting evidence.
Evidence
Authored by
15 researchersIf this is your work, this is how we attribute it on Fit Body Science. CG Turgut is listed as the lead author.